Innate Pharma S.A. (IPHYF)
USD 2.9
(0.0%)
USD 2.9
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 64.57 Million EUR | 4.77% |
| 2022 | 66.06 Million EUR | 10.22% |
| 2021 | 59.93 Million EUR | -20.49% |
| 2020 | 75.38 Million EUR | 48.19% |
| 2019 | 50.86 Million EUR | -31.95% |
| 2018 | 74.74 Million EUR | 2.94% |
| 2017 | 72.61 Million EUR | 49.44% |
| 2016 | 48.58 Million EUR | 69.42% |
| 2015 | 28.67 Million EUR | 227.35% |
| 2014 | 8.76 Million EUR | 14.33% |
| 2013 | 7.66 Million EUR | 11.33% |
| 2012 | 6.88 Million EUR | -61.05% |
| 2011 | 17.67 Million EUR | 21.18% |
| 2010 | 14.58 Million EUR | -26.73% |
| 2009 | 19.9 Million EUR | -6.87% |
| 2008 | 21.37 Million EUR | 3.67% |
| 2007 | 20.61 Million EUR | 84.36% |
| 2006 | 11.18 Million EUR | 65.15% |
| 2005 | 6.77 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.79 Million EUR | 0.0% |
| 2024 Q1 | 4.79 Million EUR | 4.78% |
| 2023 Q2 | 36.95 Million EUR | 863.8% |
| 2023 Q3 | 4.02 Million EUR | -89.1% |
| 2023 Q4 | 4.57 Million EUR | 13.49% |
| 2023 FY | 69.21 Million EUR | 4.77% |
| 2023 Q1 | 3.83 Million EUR | -88.96% |
| 2022 FY | 66.06 Million EUR | 10.22% |
| 2022 Q2 | 35.05 Million EUR | 391.61% |
| 2022 Q1 | 7.13 Million EUR | -77.23% |
| 2022 Q4 | 34.73 Million EUR | 38.98% |
| 2022 Q3 | 24.99 Million EUR | -28.71% |
| 2021 Q2 | 33.7 Million EUR | 603.31% |
| 2021 Q3 | 6.8 Million EUR | -79.82% |
| 2021 Q4 | 31.31 Million EUR | 360.31% |
| 2021 FY | 59.93 Million EUR | -20.49% |
| 2021 Q1 | 4.79 Million EUR | -87.33% |
| 2020 Q4 | 37.84 Million EUR | 25.52% |
| 2020 Q1 | 7.87 Million EUR | -83.97% |
| 2020 Q2 | 39.27 Million EUR | 398.67% |
| 2020 Q3 | 30.14 Million EUR | -23.23% |
| 2020 FY | 75.38 Million EUR | 48.19% |
| 2019 Q2 | 39.05 Million EUR | 667.32% |
| 2019 Q1 | 5.08 Million EUR | -37.82% |
| 2019 Q3 | 9.48 Million EUR | -75.72% |
| 2019 Q4 | 49.13 Million EUR | 418.16% |
| 2019 FY | 50.86 Million EUR | -31.95% |
| 2018 Q2 | 3.39 Million EUR | 0.0% |
| 2018 FY | 74.74 Million EUR | 2.94% |
| 2018 Q1 | 3.39 Million EUR | -48.56% |
| 2018 Q4 | 8.18 Million EUR | 0.0% |
| 2018 Q3 | 8.18 Million EUR | 141.1% |
| 2017 Q2 | 6.49 Million EUR | 0.0% |
| 2017 FY | 72.61 Million EUR | 49.44% |
| 2017 Q4 | 6.59 Million EUR | 0.0% |
| 2017 Q3 | 6.59 Million EUR | 1.59% |
| 2017 Q1 | 6.49 Million EUR | 443.14% |
| 2016 FY | 48.58 Million EUR | 69.42% |
| 2016 Q1 | 1.75 Million EUR | 18.05% |
| 2016 Q2 | 1.75 Million EUR | 0.0% |
| 2016 Q3 | 1.19 Million EUR | -32.01% |
| 2016 Q4 | 1.19 Million EUR | 0.0% |
| 2015 FY | 28.67 Million EUR | 227.35% |
| 2015 Q4 | 1.49 Million EUR | 0.0% |
| 2015 Q3 | 1.49 Million EUR | 1762.5% |
| 2015 Q2 | 80 Thousand EUR | 0.0% |
| 2015 Q1 | 80 Thousand EUR | -10.11% |
| 2014 Q1 | 2.43 Million EUR | -4.59% |
| 2014 FY | 8.76 Million EUR | 14.33% |
| 2014 Q4 | 89 Thousand EUR | 0.0% |
| 2014 Q3 | 89 Thousand EUR | -96.34% |
| 2014 Q2 | 2.43 Million EUR | 0.0% |
| 2013 Q4 | 2.55 Million EUR | 0.0% |
| 2013 Q3 | 2.55 Million EUR | 27.85% |
| 2013 Q1 | 1.99 Million EUR | -10.56% |
| 2013 FY | 7.66 Million EUR | 11.33% |
| 2013 Q2 | 1.99 Million EUR | 0.0% |
| 2012 Q3 | 2.23 Million EUR | 0.0% |
| 2012 Q4 | 2.23 Million EUR | 0.0% |
| 2012 FY | 6.88 Million EUR | -61.05% |
| 2011 FY | 17.67 Million EUR | 21.18% |
| 2010 FY | 14.58 Million EUR | -26.73% |
| 2009 FY | 19.9 Million EUR | -6.87% |
| 2008 FY | 21.37 Million EUR | 3.67% |
| 2007 FY | 20.61 Million EUR | 84.36% |
| 2006 FY | 11.18 Million EUR | 65.15% |
| 2005 FY | 6.77 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 25.598% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1212.955% |
| SQZ Biotechnologies Company | 85.61 Million USD | 24.584% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -118.489% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -73.316% |
| Mesoblast Limited | 5.9 Million USD | -994.036% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -4199.224% |
| Genus plc | 147.7 Million USD | 56.283% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -635.486% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -4713.107% |
| Marizyme, Inc. | 19.23 Million USD | -235.606% |
| ContraFect Corporation | 56.88 Million USD | -13.502% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -674.313% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -1364.613% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -4266.52% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -2114.156% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -2214.041% |
| MultiCell Technologies, Inc. | 567.42 USD | -11379477.738% |
| Accustem Sciences Inc. | 3.74 Million USD | -1623.513% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 24.871% |
| EV Biologics, Inc. | 531.96 Thousand USD | -12038.085% |
| Q BioMed Inc. | 3.43 Million USD | -1778.877% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -161.258% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -16474.855% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -2357.449% |
| Biomind Labs Inc. | 994.18 Thousand USD | -6394.787% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 71.365% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -861.147% |
| Skye Bioscience, Inc. | 13.54 Million USD | -376.618% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -3051.747% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 258380.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1180.631% |
| IMV Inc. | 37.7 Million USD | -71.231% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -303.304% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -3418.619% |
| GB Sciences, Inc. | 1.42 Million USD | -4445.554% |
| Alpha Cognition Inc. | 9.7 Million USD | -565.286% |
| HST Global, Inc. | 140.9 Thousand USD | -45724.551% |
| CSL Limited | 3.44 Billion USD | 98.128% |
| Halberd Corporation | 74.84 Thousand USD | -86175.086% |
| Enzolytics Inc. | 2.17 Million USD | -2862.597% |
| Resverlogix Corp. | 12.71 Million USD | -407.945% |
| Affymax, Inc. | 39.38 Million USD | -63.942% |
| SYBLEU INC | 160.87 Thousand USD | -40036.503% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -1668.699% |
| argenx SE | 1.53 Billion USD | 95.789% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -12.413% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -6084.866% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -3988.378% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1796.341% |
| AVAX Technologies, Inc. | 7.31 Million USD | -783.279% |
| Zenith Capital Corp. | 8.94 Million USD | -622.017% |
| Genscript Biotech Corporation | 825.34 Million USD | 92.177% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -370544.624% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -2529.803% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -37548.17% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 34.995% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -3569.421% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -3174.284% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -3363.368% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -494.184% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -3261.435% |
| BioStem Technologies, Inc. | 22.97 Million USD | -181.047% |
| ONE Bio Corp. | 6.44 Million USD | -902.034% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -35478.698% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -4735.143% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -5640.015% |
| Agentix Corp. | 1.37 Million USD | -4607.105% |
| LadRx Corporation | 3.81 Million USD | -1593.954% |
| Cell Source, Inc. | 4.32 Million USD | -1392.829% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -15441.098% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -6891.803% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -6891.803% |
| NovAccess Global Inc. | 2.46 Million USD | -2517.603% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -2584.897% |
| Itoco Inc. | 919.14 Thousand USD | -6925.022% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -1423.447% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -5670.331% |
| Kadimastem Ltd | 2.41 Million USD | -2579.129% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -24570.839% |
| CytoDyn Inc. | 18.05 Million USD | -257.57% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -256445.751% |
| Mobile Lads Corp. | 554.54 Thousand USD | -11543.759% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -29239.598% |
| Qrons Inc. | 643.67 Thousand USD | -9931.429% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -4447.849% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -2795.673% |
| Rebus Holdings, Inc. | 664 Thousand USD | -9624.398% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -3454.99% |
| International Stem Cell Corporation | 5.27 Million USD | -1125.005% |
| Bioxytran, Inc. | 3.82 Million USD | -1590.249% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -122558.714% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -317306.479% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -78.046% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -3890.729% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -8675.065% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1975.538% |
| Neutra Corp. | 243.82 Thousand USD | -26382.543% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -269.88% |
| PureTech Health plc | 144.59 Million USD | 55.345% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -215.131% |
| IXICO plc | 4.7 Million USD | -1271.787% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -634.0% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 45.163% |
| CSL Limited | 3.89 Billion USD | 98.341% |
| Cellectis S.A. | 97.32 Million USD | 33.652% |